Digital pill offers chance of new life to old drugs image

Financial Times, November 22, 2017
FT Staff, quoting I. Glenn Cohen (Faculty Director)


Read the Full Article

From the article:

Amid broader concerns about how medical information may be used, Proteus says that its product complies with “all applicable laws and standards” on data protection. Patients can turn off the system at any time.

[I.] Glenn Cohen, a bio-ethicist at Harvard who was commissioned by Otsuka to examine potential ethical issues surrounding the technology, says he knows of no plans to use it in coercive settings — for example as a condition of a prisoner being released from jail.

Prof Cohen adds: “Not only would I feel more secure on this than [with] my Facebook data, but many other things I store electronically — including my Harvard emails.”

Read the full article here

bioethics biotechnology fda health law policy i. glenn cohen pharmaceuticals regulation